In the current evolving landscape of myeloma therapies, no recommended salvage strategy exists for patients with relapsed multiple myeloma (MM) after initial successful autologous stem cell transplantation (ASCT) and therapeutic options extend from conventional chemotherapy and novel agents to second autologous and allogeneic transplants. In this article, we summarize the documented evidence about the utilization of second ASCT in patients with relapsed MM after a primary auto-graft and discuss the correct timing for such a salvage approach, the individual characteristics of patients who will benefit more, as well as the therapeutic role of second ASCT in the modern era of forthcoming anti-myeloma treatments.
Michèle Cavo, S. Vincent Rajkumar, Antonio Palumbo, Philippe Moreau, Robert Z. Orlowski, Joan Bladé, Orhan Sezer, Heinz Ludwig, Meletios A Dimopoulos, Michel Attal, Pieter Sonneveld, Mario Boccadoro, Kenneth C. Anderson, Paul G. Richardson, William Bensinger, Hans Erik Johnsen, Nicolaus Kroeger, Gösta Gahrton, P. Leif Bergsagel, David H. Vesole, Hermann Einsele, Sundar Jagannath, Rubén Niesvizky, Brian G.M. Durie, Jesús F. San Miguel, Sagar Lonial
Katja Weisel, Chantal Doyen, Meletios A Dimopoulos, Adrian Yee, Juan José Lahuerta, Amber Martin, Karin Travers, Eric Druyts, Kabirraaj Toor, Niels Abildgaard, Jin Lu, Jan Van Droogenbroeck, Catarina Geraldes, Mario Petrini, Laurent Voillat, Éric Voog, Thierry Façon
Discussion(0)
No comments yet. Be the first to comment.